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Maria Rostovskaya, Nicholas Bredenkamp and Austin Smith
Wellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, Tennis Court Road,
Cambridge CB2 1QR, UK
Human pluripotent stem cells can in principle be used as a source of any
differentiated cell type for disease modelling, drug screening, toxicology testing
or cell replacement therapy. Type I diabetes is considered amajor target for stem
cell applications due to the shortage of primary human beta cells. Several proto-
cols have been reported for generating pancreatic progenitors by in vitro
differentiation of human pluripotent stem cells. Here we first assessed one of
these protocols on a panel of pluripotent stem cell lines for capacity to engender
glucose sensitive insulin-producing cells after engraftment in immunocompro-
mised mice. We observed variable outcomes with only one cell line showing a
low level of glucose response.We, therefore, undertook a systematic comparison
of different methods for inducing definitive endoderm and subsequently pan-
creatic differentiation. Of several protocols tested, we identified a combined
approach that robustly generated pancreatic progenitors in vitro from both
embryo-derived and induced pluripotent stem cells. These findings suggest
that, although there are intrinsic differences in lineage specification propensity
between pluripotent stem cell lines, optimal differentiation procedures may
consistently direct a substantial fraction of cells into pancreatic specification.1. Introduction
Human pluripotent stem cells (PSC) represent a renewable source of differen-
tiated cell types for fundamental and applied research and potentially for use
in cell-based therapies including for type I diabetes. Moreover, generation of
human induced pluripotent stem cells (hiPSC) from somatic cells opens the
possibility of producing patient-specific cells for autologous transplantation
[1,2]. However, to realize their potential for study of beta cell biology and
immunology, and for cell therapy applications, generically applicable methods
are needed for efficient differentiation to pancreatic lineages.
Multiple protocols have been described for converting PSC to pancreatic pro-
genitors in vitro [3–11]. In vivo development of the pancreas is preceded by
specification of definitive endoderm (DE) [12–14]. The main inducer of DE in
the vertebrate embryo and during in vitro differentiation from PSC is Nodal sig-
nalling [15,16], which can be simulated by high doses of other TGFb family
members such as Activin A or GDF8 [17,18]. This process also requires transcrip-
tional activation by beta-catenin [15,19], which can be stimulated by Wnt3a or by
chemical inhibition of GSK3b. Additional signals such as bone morphogenetic
proteins (BMPs), fibroblast growth factors (FGFs) and inhibition of PI3K/Akt
may also contribute to DE specification [4,19,20], although their precise modes
of action remain undefined.
The DE forms primitive gut, which undergoes patterning along the anterior–
posterior axis to establish foregut, midgut and hindgut domains instructed by
local signalling cues, including Wnt, BMP, FGF and retinoic acid [21]. Further,
guided by a combination of signals received from neighbouring tissues [22],
cells locatedat the junctionof foregut andmidgut become specified to the pancrea-
tic anlage and evaginate to form the dorsal and ventral pancreatic buds [23]. At
Table 1. Conditions for deﬁnitive endoderm differentiation of human PSCs.
protocol references stage 1
DE-1 Loh et al. [4] 100 ng ml21 Activin A
100 nM PI103
3 mM Chiron
10 ng ml21 FGF2
3 ng ml21 BMP4
21 day
100 ng ml21 Activin A
100 nM PI103
20 ng ml21 FGF2
250 nM DM3189
22 days
DE-2 Touboul et al. [20] 100 nM PI103
100 ng ml21 Activin A
20 ng ml21 FGF2
10 ng ml21 BMP4
23 days
DE-3 Rezania et al. [7] 100 ng ml21 GDF8
3 mM Chiron
21 day
100 ng ml21 GDF8
0.3 mM Chiron
21 day
100 ng ml21 GDF8
21 day
DE-4 D’Amour et al. [15] 100 ng ml21 Activin A
25 ng ml21 Wnt3a
21 day
0.2% FBS
100 ng ml21 Activin A
22 days
DE-5 Cheng et al. [32] 100 ng ml21 Activin A
40 ng ml21 Wnt3a
21 day
0.5 ng ml21 BMP4
10 ng ml21 bFGF
100 ng ml21 Activin A
10 ng ml21 VEGF
24 days
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progenitors, which later form all lineages in pancreas—acinar,
ductal and endocrine [24,25]. They express and are critically
dependent on the transcription factor PDX1, pancreatic and
duodenal homeobox 1. As its name implies, PDX1 is not exclu-
sive to pancreas but is expressed in a region of posterior foregut
including stomach and duodenum [26,27].
Based, in large part, on the elucidation of major signals
operating during specification of pancreatic epithelium in the
mouse embryo, methods have been devised to generate
PDX1-expressing progenitors from PSC in vitro involving var-
ious combinations of factors and timings of treatment [3–5].
While the requirement for retinoic acid and BMP inhibition is
well accepted, the role ofFGFs [28] andWnt [5] for in vitro induc-
tion has been challenged [4]. These apparent discrepancies are
difficult to resolve because of the lack of reference data from
the human embryo and because the existing protocols have
not been evaluated side-by-side across a panel of PSC lines.
Herewe systematically compared approaches for PSC speci-
fication to DE and further to PDX1-expressing presumptive
pancreatic endoderm using both embryo-derived pluripotent
stem cells (hESC) and hiPSC. Our data define conditions for
reliable generation of pancreatic derivatives from different PSC.2. Material and methods
For the detailed description of culture and differentiation proto-
cols, see the electronic supplementary material, Supplementary
Experimental Procedures.(a) Pluripotent stem cell lines and culture
hESC lines used in the study were H9 [29] and Shef6 [30]. Trans-
gene-free hiPSC cells were derived previously in our laboratory
from human fibroblasts (FiPS) and adipose tissue cells (AdiPS)
by expression of OCT4, SOX2, KLF4 and cMYC using Sendai
virus [31]. PSC were cultured either on feeder layers of
g-irradiated mouse embryonic fibroblasts in KnockOut Serum
Replacement and FGF2 containing medium (KSR/MEF), or on
Matrigel-coated plates (Corning) in Essential 8 medium (E8,
Gibco Life Technologies).
(b) Definitive endoderm differentiation
The DE differentiation was performed with H9 hESC and FiPS
cells expanded in KSR/MEF or E8 conditions, according to the
five methods summarized in table 1. Data were collected from
six independent experiments.
(c) Pancreatic differentiation
For pancreatic differentiation from the DE stage, we employed
six published protocols summarized in table 2. Data were
collected from 12 independent experiments. The pancreatic pro-
genitors were further differentiated to insulin-producing cells
using a recently described protocol [7].
(d) Quantitative RT-PCR
Total RNAwas extracted with RNeasy Mini Kit (Qiagen) and up
to 1 mg was used for reverse transcription with SuperScript III
(Invitrogen). Quantitative PCR was performed with TaqMan
Fast Universal PCR Master Mix (Applied Biosystems) using
Table 2. Conditions for differentiation to PDX1-expressing progenitors.
protocol references
stage 2 stage 3 stage 4a
validation of differentiation
potential of the resulted cells
primitive gut
endoderm
PDX11, presumptive pancreatic
endoderm
P-1 Kroon et al. [3] 2% FCS
50 ng ml21 FGF7
23 days
2 mM ATRA
250 nM SANT-1
250 nM DM3189
23 days
— formation of polyhormonal cells in
vitro;
maturation in vivo to functional
beta cells
P-2 Nostro et al. [5] 3 ng ml21 Wnt3a
50 ng ml21 FGF10
250 nm DM3189
23 days
2 mM ATRA
250 nM SANT-1
250 nM DM3189
50 ng ml21
FGF10
23 days
— formation of polyhormonal cells in
vitro
P-3 Loh et al. [4] 250 nM DM3189
4 mM IWP2
500 nM
PD0325901
2 mM ATRA
21 day
2 mM ATRA
250 nM SANT-1
250 nM DM3189
500 nM
PD0325901
23 days
— not reported
P-4 Rezania et al. [7]/
Pagliuca et al. [6]
250 mM ascorbic
acid
50 ng ml21 FGF7
22 days
250 mM
ascorbic acid
50 ng ml21
FGF7
250 nM SANT-1
1 mM ATRA
100 nM DM3189
200 nM TPB
23 days
— differentiation to monohormonal
insulinþ cells in vitro;
maturation in vivo to functional
beta cells
P-5 Rezania et al. [7] 250 mM
ascorbic acid
2 ng ml21 FGF7
250 nM SANT-1
100 nM ATRA
200 nM DM3189
100 nM TPB
23 days
P-6 Pagliuca et al. [6] 250 mM
ascorbic acid
50 ng ml21
FGF7
250 nM SANT-1
100 nM ATRA
25 days
aStage 4 conditions were applied only after protocol 4, constituting protocols 5 and 6.
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are listed in the electronic supplementary material, table S1.
GraphPad Prism software was employed for data representation.
(e) Flow cytometry
For surface marker staining, cells were dissociated using 0.5 mM
EDTA and incubated with directly conjugated antibodies (elec-
tronic supplementary material, table S2) diluted in phosphate-
buffered saline (PBS) with 2% fetal calf serum for 1 h at þ48C.
For co-staining with intracellular markers, cells were then fixed
with Fixation Buffer (00-8222-49, eBiosciences) for 30 min atþ48C and incubated with primary and secondary antibodies, as
below, omitting methanol treatment.
For intracellular flow cytometry, cells were harvested using
TrypLe Select (Gibco Life Technologies), washed and incubated
with Fixation Buffer (00-8222-49, eBiosciences) for 30 min at
þ48C. After washing with Permeabilization Buffer (00-8333-56,
eBiosciences), cells were treated with 90% methanol for 30 min
on ice, followed by three rounds of washing. Incubations with
primary and secondary antibodies (electronic supplementary
material, table S2) diluted with 5% donkey serum (Sigma-
Aldrich) in Permeabilization Buffer were for 1 h at þ48C. Analysis
was performed on a BD Fortessa LSR using FlowJo software.
Table 3. Grafts of PSC-derived pancreatic progenitors generated according to Kroon et al. [3] in NOD SCID mice.
cell line
total number of
transplanted mice
maximum time
of follow-up
(weeks)
incidence of
tumours, detected/
analysed (% from
grafts)
number of non-
tumourous grafts,
detected/total
analysed
mice with detectable
GSIS, detected/analysed
after 21–22 weeks
H9 8 21 0/8 8 4/4
Shef6 8 21 1/8 (12.5%) 7/8 0/4
AdiPS 8 22 0/8 8 0/3
FiPS 8 19 3/8 (37.5%) 5/8 n.a.
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Cells were fixed with 4% buffered formaldehyde for 15 min at
room temperature, permeabilized with 0.5% Triton X-100 in
PBS for 10 min and blocked with 3% bovine serum albumin
(BSA) and 0.1% Tween-20 in PBS for 30 min at room tempera-
ture. Incubation with primary antibodies (electronic
supplementary material, table S3) diluted in blocking solution
was carried out overnight at þ48C, then secondary antibodies
were added for 1 h at room temperature. Cells were counter-
stained with DAPI and slides mounted with Prolong Diamond
Antifade Mountant (Life Technologies).
(g) Kidney capsule engraftment
PSC (H9, Shef6, AdiPS, FiPS) were differentiated to PDX1-
expressing progenitors according to Kroon et al. [3]. The cells were
gently scraped and washed with DMEM/F12 containing 0.1%
BSA. After centrifugation cell pellets were transplanted under
kidney capsules ofNOD/SCIDmice (9–12-week-oldmales;Charles
River) using a glass micropipette (0.5–1  107 cells per mouse).
(h) C-peptide assay
Glucose-stimulated human C-peptide secretion was assayed
by collecting blood samples from mice after overnight fast
(16 h) and 30 min following intraperitoneal administration of
D-(þ)-Glucose (2 g/kg body weight; 30% solution; Sigma).
Plasma was obtained after centrifugation of the blood samples
(1600g for 10 min at 48C) and human C-peptide levels were
measured using an electrochemiluminescence assay (Meso
Scale Discovery). Each assay contained a series of standards
with concentrations of 0, 7.6, 22.8, 68, 204, 611, 1833, 5500 and
16 500 pmol l21. The lower limit of detection (LLOD) was deter-
mined by the software analysing signals across the three lower
concentration standards.
(i) Immunohistological analysis
Recovered grafts and cell aggregates cultured on membrane
at stage 7 of differentiation were rinsed in PBS and fixed for
1 hour in 4% paraformaldehyde. Following fixation, grafts
were rinsed three times in PBS and incubated overnight at 48C
in 30% sucrose solution. The samples were then frozen in OCT
solution and stored at 2808C before being cryosectioned at
7 mm thickness. Sections were rinsed in PBS for 5 min and
blocked with an appropriate serum (5%) for 1 h. Primary anti-
bodies at the appropriate dilution were added for 2 h at room
temperature, followed by washing in PBS and incubation with
secondary antibodies for 45 min at room temperature. Sections
were then washed and mounted in Vectashield mounting
medium. Sections were visualized using a Zeiss ApoTome
fluorescence microscope.3. Results
(a) In vivo maturation of pancreatic progenitors
generated from PSC
In order to assess the propensity of multiple PSC lines to form
insulin-producing cells in vivo, we first used a seminal method
for generation of pancreatic progenitors capable of maturation
to glucose-responsive cells in vivo [3]. This method was orig-
inally established using two proprietary hESC cell lines
CyT49 and CyT203. We applied the method to two well
characterised hESC lines, H9 and Shef6, and two hiPSC
lines and grafted differentiated cell populations under the
kidney capsules of NOD/SCID immunodeficient mice.
We confirmed engraftment in all transplanted mice (table 3).
In some cases tumour formation was observed with the highest
incidence rate in mice engrafted with cells differentiated from
FiPS. The non-tumourous grafts were analysed histologically at
different time points: eight weeks, 13–15 weeks and 21–22
weeks after transplantation. A low proportion of insulin-expres-
sing cells was detected as early as eight weeks after grafting
(figure 1a). The number of insulin-positive cells gradually
increased over time. Only a low number of cells expressed gluca-
gon (figure 1b). We detected a proportion of polyhormonal
INSþGCGþ cells in the Shef6-derived transplants whereas
grafts recoveredfromH9andAdiPS-transplantedmicecontained
monohormonal cells expressing either insulin or glucagon.
The grafts were composed mostly of cells of human origin
as shown by immunostaining for human nuclei (figure 1c).
The size of the grafts and frequency of insulin-positive cells
were highly variable (figure 1d ). The largest grafts were
formed from H9 derivatives. However, these contained the
lowest proportion of insulin-positive cells and displayed a
number of other uncharacterised cell types. The grafts gener-
ated by all cell lines often had a cystic morphology (n ¼ 17,
out of 32), with insulin-positive cells lining the cavities, and
not displaying the structure of pancreatic islets.
To assess functionality of endocrine cells in the grafts, we
tested glucose-stimulated C-peptide secretion at different time
points. We could reliably detect human C-peptide only in mice
grafted with H9-derived cells after 21 weeks post-transplant
(table 3, figure 1e). Two out of fourmice had a lowbut detectable
fasting level of C-peptide (4.7 and 30.4 pM; LLOD of the assay
was 3.48 pM). Administration of glucose stimulated C-peptide
secretion in all four of these mice, albeit at a low level.
We conclude that differentiated populations derived from
four hESC and hiPSC lines using this protocol could generate
low numbers of insulin-expressing cells in vivo, but these did
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Figure 1. In vivo maturation of presumptive pancreatic endoderm generated from PSC according to Kroon et al. [3]. (a) Immunostaining for insulin of grafts eight
weeks post-transplant derived from differentiated H9, Shef9 and AdiPS. (b) Immunostaining for insulin and glucagon, or (c) human nuclei of grafts 21–22 weeks
post-transplant. (d ) Immunostaining for insulin of grafts obtained 21–22 weeks after transplanting; representative images showing transversal sections of whole
grafts. The images are tiled from multiple fields of view, scale bar for all 250 mm. (e) Glucose-induced C-peptide release in mice engrafted with H9-generated cells.
Dotted line indicates lower limit of detection (3.48 pmol l21), as defined by standards measurements.
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no or low glucose responsiveness. Furthermore, the incidence
of teratomas points to persistence of undifferentiated PSC in
some cases.(b) Definitive endoderm differentiation in vitro
To assess whether the PSC used in our study may have
some fundamental impairment in capacity to produce
cells of pancreatic lineage, we systematically evaluated
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pancreatic progenitors.
The efficiency of DE formation was evaluated by flow cyto-
metry for co-expression of the surface markers CD117 and
CXCR4. A key transcription factor marker of DE, SOX17 [33],
was present in almost all CD117þCXCR4þ cells (electronic sup-
plementary material, figure S1), confirming that co-expression
of CD117 and CXCR4 is a reliable readout for quantification
of DE production, as previously proposed [5,34–36].
Standard protocols for PSC maintenance employ KSR and
MEF. However, more defined culture conditions such as E8
medium have been recently developed. We therefore assessed
the efficiency of DE differentiation from PSC expanded using
KSR/MEF or E8 culture. We examined five published proto-
cols for DE induction (summarized in table 1). We found
that protocols DE-4 and DE-5 were poorly compatible with
cells expanded in KSR/MEF, often resulting in complete cell
death (8/10 experiments). The efficiencies of protocols DE-1,
DE-2 and DE-3 were similar for KSR/MEF or E8 cultures
(figure 2a, electronic supplementary material, table S5). There-
fore, we used PSC maintained in both conditions for further
analysis of DE induction using protocols DE-1, DE-2 and
DE-3, and only E8-cultured PSC for protocols DE-4 and DE-
5. We compared potential of hESC (H9) and hiPSC (FiPS) to
generate DE using all five protocols. In all conditions except
for DE-2, FiPS reproducibly showed rather higher efficiency
of DE production than H9 (figure 2b,d, electronic supplemen-
tary material, table S6). Variation in lineage propensity among
PSC lines is well documented [5,15]. We evaluated efficiency
among the five chosen protocols for DE induction using com-
bined results from H9 and FiPS differentiation. Protocol DE-1
was significantly more efficient relative to all the others,
p-value, 0.05 (figure 2b,d, electronic supplementary material,
table S7). Moreover, this protocol showed less difference
between H9 and FiPS (median efficiencies 76.6% versus
94.5%, respectively) compared with most other conditions.
Flow cytometry results were validated by immunostaining
of differentiated H9 hESC (figure 2e). We noted that the cell
populations derived from the less efficient conditions (proto-
cols DE-2, DE-4 and DE-5) still retained a large proportion of
OCT4-highly positive cells, sometimes showing co-expression
with a low level of SOX17. These cells might be primitive
streak-like cells in process of specification to DE or may be
mis-specified cells. Residual OCT4 expression was confirmed
at the mRNA level by qRT-PCR (figure 2c). We also observed
that cells differentiated using protocol DE-4 reproducibly con-
tained only a relatively small proportion of SOX17-positive
cells, but that these cells exhibited intense staining. The rela-
tively high expression of SOX17 and HHEX mRNA at the
population level (figure 2c) is therefore somewhat misleading
for this protocol. This observation underlines that differen-
tiation efficiency must be evaluated by protein expression at
the cellular level and not solely by qRT-PCR.
We conclude that protocol DE-1 (performed according to
Loh et al. [4]) has a higher efficiency and reproducibility of DE
generation compared with the other protocols tested.(c) Generation of PDX1þ progenitors
We next sought to compare and evaluate existing methods for
generation of early pancreatic progenitors from PSC-derived
DE. We generated DE cells using the DE-1 protocol as above
and then applied a range of conditions reported to specifyDE to primitive gut tube and further to PDX1-expressing
presumptive pancreatic endoderm (table 2). Protocols P-1 [3]
and P-2 [5] have previously been reported to generate PDX1-
positive progenitors that could differentiate further into
polyhormonal endocrine cells expressing both glucagon and
insulin in vitro. Additionally, cells produced using protocol
P-1 were shown to mature to monohormonal glucose-respon-
sive cells in vivo [3]. Protocol P-3 was reported as a method for
production of PDX1-positive cells without further evaluation
[4]. Protocol P-4 was used in two recent reports by Rezania
et al. [7] and Pagliuca et al. [6], to obtain PDX1-expressing
progenitors (called stage 3 cells, S3). In these two studies, differ-
ing additional steps were applied after P-4 to enrich for PDX1þ
NKX6.1þdouble-positive cells, called stage 4 cells, S4 (protocols
P-5 and P-6 in our experimental set-up). Those progeni-
tors displayed capacity to differentiate to monohormonal
insulin-expressing cells both in vitro and in vivo [6,7].
We first compared the capacity of PSC cultured in KSR/
MEF or E8 to differentiate beyond DE to PDX1-expressing
cells. We quantified outcomes by intracellular flow cytome-
try. Protocols P-5 and P-6 were more efficient using
E8-cultured cells, and protocol P-2 was more efficient starting
from cells in KSR/MEF (figure 3a, electronic supplementary
material, table S8). However, the outcome for KSR-cultured
cells was more variable for each protocol than for cells main-
tained in E8, as indicated by the coefficient of variation.
Therefore, we decided to use only cells cultured in E8 for
further comparisons between the protocols.
We examined the potential of H9 and FiPS to generate
PDX1þ cells using the six protocols. Interestingly, there was
no significant difference in production of PDX1-positive cells
between H9 and FiPS cells using all tested methods
(figure 3b, electronic supplementarymaterial, table S9). By ana-
lysing combined results of H9 and FiPS differentiation, we
found the lowest proportion of PDX1-expressing cells after pro-
tocol P-2 (median 5.1%), and higher levels after protocols P-1
and P-3 (median 31.0% and 41.1%, respectively), although pro-
tocol P-3 often resulted in high levels of cell death for both cell
lines. Protocol P-4 (stage 3 according to [6,7]) yielded signifi-
cantly greater numbers of PDX1-positive cells (median 62.6%)
compared with the other three conditions. PDX1 was further
elevated applying protocols P-5 and P-6 (stage 4), resulting
in conversion of the vast majority of cells to PDX1-positive
progenitors (95.3% and 92.6%, respectively) (figure 3b,c,d,
electronic supplementary material, table S10).
Progenitors generated from PSC co-expressed PDX1, SOX9
and FOXA2 (figure 4a). We also confirmed upregulation
of NKX6.1 in the stage 4 cells after protocols P-5 and P-6,
and emergence of PDX1þ NKX6.1þ double-positive cells
(figure 4b,c). Protocol P-3 also reproducibly resulted in an elev-
ated level of NKX6.1, but the protein was present only in cells
with low or undetectable PDX1 (figure 4c). This observation
suggests that these cells either belong to another lineage, or rep-
resent more advanced differentiated endocrine cells. The latter
explanation would be consistent with the expression of NGN3
and NEUROD1 mRNA after protocol P-3 (figure 4b).
Finally, we assessed whether PDX1þ progenitors from
protocol P-5 could be further differentiated to insulin-
positive cells using a recently described transwell culture
system [7]. Expression of markers characteristic for hormone-
expressing cells was shown by qPCR and antibody staining
(figure 4d–f) and insulin synthesiswas confirmedby flow cyto-
metry for C-peptide. Glucagon-positive cells were also present
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Figure 2. PSC differentiation to definitive endoderm. (a) PSC cultured in E8 or KSR/MEF conditions were differentiated using the five protocols and assayed by flow
cytometry for CD117/CXCR4. Conditions resulting in no surviving cells were assigned 0% efficiency ( protocols DE-4 and DE-5). Box plots show the results of inde-
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monohormonal. However, the frequency of insulin-positive
cells was only 1%, lower than reported previously for a single
hESC cell line [7], and prohibited reliable assay of glucose
sensitivity or engraftment.4. Discussion
Efficient generation of pancreatic lineage derivatives is
important for research in human beta cell biology, drug test-
ing, immunological studies of the aetiology of type I diabetes,
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cols have been developed to use PSC as a source of pancreatic
lineage in vitro [4–11] and in vivo [3,6,7], however, those have
generally been validated with a single or very limited
number of cell lines. Furthermore, very few studies have
examined the capacity of hiPSC for in vivo maturation [37].
In this study, we first assessed pancreatic progenitors
derived from two hESC and two hiPSC lines using a pre-
viously published method [3] for the ability to produce
functional beta cells in vivo. For engraftment we used differ-
entiating cells at the onset of PDX1 expression. PDX1 is theearliest marker for pancreatic progenitors that give rise to
all pancreatic lineages [24,25]. However, other cell types in
stomach and duodenum also express PDX1 during develop-
ment [26,27], and may be present in the differentiating
cultures. PDX1-expressing cell populations produced from
all PSC lines were able to produce some insulin-expressing
cells in vivo. Notably, most grafts contained large cysts lined
with insulin-positive cells, which did not form islet-like struc-
tures. Interestingly, in a later study the authors of the original
method revealed that approximately one half of grafts exhibi-
ted such morphology with detectable glucose-stimulated
200 mm
PDX1
FOXA2
SOX9
PDX1
PDX1 SOX9 DAPI
FOXA2 PDX1 DAPI
pr
ot
oc
ol
 P
-5
 (S
4 c
ell
s)
(a) (b)
(c)
(d)
PDX1 NKX6.1 PDX1 NKX6.1 DAPI
100 mm
pr
ot
oc
ol
 P
-5
(S
4 c
ell
s)
pr
ot
oc
ol
 P
-3
1 2 3 4 5 6 hPSC
0
0.0005
0.0010
0.0015
NKX6.1
1 2 3 4 5 6 hPSC
0
0.001
0.002
0.003
NGN3
1 2 3 4 5 6 hPSC
0
0.02
0.04
0.06
SOX9
1 2 3 4 5 6 hPSC
0
0.001
0.002
0.003
0.004
0.005
NEUROD1
1 2 3 4 5 6 hPSC
0
0.01
0.02
0.03
0.04
n
o
rm
al
iz
ed
 to
G
A
PD
H
n
o
rm
al
iz
ed
 to
G
A
PD
H
n
o
rm
al
iz
ed
 to
G
A
PD
H
n
o
rm
al
iz
ed
 to
G
A
PD
H
n
o
rm
al
iz
ed
 to
G
A
PD
H
PDX1
*
***
*
*
* *
protocol P-
protocol P-
protocol P-
IN
S
GC
G
NG
N3
NK
X6
.1
PD
X1
NK
X2
.2
NE
UR
OD
1
10–7
10–6
10–5
10–4
10–3
10–2
10–1
1
10
n
o
rm
al
iz
ed
 to
 G
A
PD
H
H9 hESC
H9-S7
( f )
H9, stage 7
530/30 488nm-A
67
0/
14
 6
40
nm
-A
0.1 0.9
0.598.5IN
SU
LI
N
C-peptide
530/30 488nm-A
67
0/
14
 6
40
nm
-A
2.0 0.3
1.796.0
INSULIN
G
LU
CA
G
O
N
530/30 488nm-A
67
0/
14
 6
40
nm
-A
0.1 0
0.299.7
Ig
G
-A
le
x
a6
47
IgG-Alexa488
H9, stage 7
INSULIN INSULIN DAPI
H
9-
sta
ge
 7
100 mm
(e)
protocol P-1 (Kroon et al. [3])
protocol P-2 (Nostro et al. [5])
protocol P-3 (Loh et al. [4])
protocol P-4 (Rezania et al. [7]/
                     Pagliuca et al. [6]; stage 3)
protocol P-5 (Rezania et al. [7]; stage 4)
protocol P-6 (Pagliuca et al. [6]; stage 4)
hPSC undifferentiated
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
0 102 103 104 105
0
102
103
104
105
Figure 4. Characterisation of PSC-derived presumptive pancreatic endoderm. (a) Immunostaining for PDX1, FOXA2 and SOX9 in differentiated cells derived from H9
cells using protocol 5 (S4 stage). (b) Gene expression in differentiated cells derived from PSC using the six protocols. Whisker plots summarize the results for
independent biological replicates, and individual values are shown as dots. (c) Immunofluorescent staining for PDX1 and NKX6.1. A proportion of cells generated
by protocol 5 (S4 stage) co-expressed PDX1 and NKX6.1, whereas the NKX6.1þ cells derived using protocol 3 did not have detectable PDX1. Insets show higher
magnification of regions marked with a white square. (d ) Gene expression after further differentiation of PDX1þ cells generated from H9 using protocol 5 (S7 stage,
[7]). (e) Immunostaining for insulin and ( f ) flow cytometry results for insulin (rabbit anti-human antibody) in combination with glucagon, and insulin (mouse anti-
human antibody) with C-peptide in S7 stage cells derived from H9.
rstb.royalsocietypublishing.org
Phil.Trans.R.Soc.B
370:20140365
9
 on October 23, 2015http://rstb.royalsocietypublishing.org/Downloaded from insulin secretion (GSIS) in those mice [38]. Our observation is
therefore not inconsistent.
We detected glucose-induced human C-peptide release
only in mice that received H9-derived grafts. Furthermore,
this response was very low. This result contrasts with the
high C-peptide level observed in most transplanted mice in
the original report [3,38]. The other difference we observed
was the appearance of polyhormonal cells co-expressing insu-
lin and glucagon in grafts from Shef6 hESC, which persisted at
21 weeks after transplant. It should be noted that we trans-
planted PSC-generated early pancreatic progenitors (PDX1þ)
whereas Kroon et al. used cells at a later stage of specification
(NKX6.1þ NGN3þ NKX2.2þ), which could potentially affect
the outcome. In their original study the protocol was validatedusing two in-house hESC lines, CyT49 and CyT203. However,
others have also reported lack of functional beta cells in trans-
plants from hiPSC derivatives following this approach [37]. Of
additional note, we observed incidences of tumour formation
from some of the transplanted cells. This indicates that cell
populations derived from PSC after differentiation using this
protocol may still contain pluripotent cells.
We investigated whether the lack of functional beta cells in
the grafts reflected intrinsic differentiation deficiencies in the
PSC used in our study. For this, we systematically evaluated
several existing methods to generate DE and subsequently
PDX1-expressing pancreatic progenitors from PSC. We
assessed efficiencies depending on the conditions of PSC
expansion, cell line and protocol. PSC are commonly
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although several more defined culture conditions have now
been developed (reviewed in [39]). We compared the outcome
of differentiation of PSC grown in KSR/MEF and E8. The
potential to generate DE was not dependent on starting con-
ditions. However, the following steps of differentiation to
pancreatic lineage were more reproducible and robust using
PSC expanded in E8 rather than in KSR/MEF. These data
suggest that the propensity of PSC for later steps of differen-
tiation may be influenced by their prior expansion conditions.
Alternatively, persistence ofMEFsmay compromise pancreatic
differentiation after DE specification. In general terms, the
superior performance of cells maintained in defined E8
mediumbodeswell for translation to protocols for good labora-
tory practice (GLP) and good manufacturing practice (GMP).
We examined different PSC lines for their capacity to pro-
duce PDX1þ progenitors. Perhaps unsurprisingly, the early
steps of differentiation were variable among lines, as observed
in previous studies [5,15]. By contrast, the outcome of the later
specification at the PDX1þ stagewas not significantly different
among lines, if differentiation was performed under optimal
conditions (i.e. feeder-free expansion and efficient induction
to DE).
Five protocols to induce DE from PSC and six protocols to
differentiate DE further to presumptive PDX1-expressing pan-
creatic endoderm were examined. We found that the protocol
reported by Loh et al. [4] was the most efficient and robust
for DE derivation among all lines that we tested. The specific
features of this method include use of FGF2 and temporal
modulation of BMP signalling (slight activation for one day
and inhibition later on). Some PSC lines could generate DE
with high efficiency using protocols that do not involve those
factors, however. Therefore, DE induction does not absolutely
require exogenous FGFs and BMP inhibition, but these signals
may improve the outcome for particular cell lines.
Among the protocols for pancreatic progenitor generation,
the recently reportedmethods by Rezania et al. [7] and Pagliuca
et al. [6]were themost efficient and reproducible for the fourPSC
lines tested.At stage3 of this protocol cells expressedPDX1witha higher frequency compared with the other approaches, and
the level and proportion were further increased during stage 4,
resulting in cell populations containing more than 90%
PDX1-expressing progenitors. Furthermore, we could further
differentiate progenitors after protocol P-5 to monohormonal
insulin-expressing cells in vitro. In the original report, insulin-
expressing cells derived using this approach could restore
glucose levels indiabeticmice after transplantation [7].However,
in our hands the yield was very low, around 1%, suggesting
further optimization is required for scalable production.
In summary, among published protocolswe identified con-
ditions for efficient and robust generation of pancreatic
progenitors, including endocrine progenitors, from different
PSC lines. However, even using the optimal conditions defined
here (stage 4 cells, protocol P-5) we have observed that terato-
mas frequently formed after grafting to immunocompromised
mice (data not shown). We therefore suggest that an attractive
alternative for cell-based therapeutic approaches to type I dia-
betes would be to define conditions that enable capture and
stable expansion of pure pancreatic progenitors.Ethics. Animal experiments were carried out under a United Kingdom
Home Office Project Licence in a designated biofacility.
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